Check for updates

OPINION ARTICLE

Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications [version 1; peer review: 3 approved, 1 not approved]

Etienne Joly

Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, 31000, France

V1 First published: 29 Apr 2020, 9:309
<https://doi.org/10.12688/f1000research.23480.1>
 Latest published: 29 Apr 2020, 9:309
<https://doi.org/10.12688/f1000research.23480.1>

Abstract

This article proposes that one should explore whether the pulmonary complications of Covid-19 can be reduced or avoided by bypassing the airway entry of the SARS-CoV-2 virus. This could possibly be achieved by injecting live SARS-CoV-2 virus intradermal (ID), subcutaneous, intra-muscular (IM) or intra-peritoneal (IP), or by targeting the virus to the digestive tract. The effectiveness and innocuity of using those various routes could be tested very rapidly in animal models, such as Macaques, Hamsters, Ferrets or Cats.

The hope is that these experiments will reveal a route of inoculation that can reliably lead to bona-fide infections, resulting in strong immune responses, with both cellular and serological components, but with much less viral replication in the lungs. This would not only hopefully reduce the incidence of pulmonary complications in the infected subjects, but would also probably reduce the amount of virus released by them via aerosols, and thus reduce the vector of contagiousity that is hardest to control, and that probably leads most effectively to viral replication in the lungs.

If those experiments in animal models reveal that one or several routes can be used effectively to reduce pulmonary pathology, a clinical trial could be conducted in human volunteers with very low risk profiles. The ID route should probably be considered as a priority, since it could double-up as a skin test to reveal the immune status of the recipients towards the SARS-CoV-2 virus.

The course of action proposed here may possibly provide a way of taking a step ahead of the virus, and if it works as hoped, could help to end the need for confinement within a matter of months, if not weeks.

Open Peer Review

Approval Status

	1	2	3	4
version 1				
29 Apr 2020	view	view	view	view

1. **Ji-Ming Chen** , Qingdao Agricultural University, Qingdao, China
2. **Ravi Kant Narayan** , Etiologically Elusive Disorders Research Network (EEDRN), New Delhi, India
Manika Verma, Etiologically Elusive Disorders Research Network (EEDRN), New Dehli, India
3. **Jonathan Yewdell** , National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, USA
4. **Mahmoud Kandeel** , College of Veterinary Medicine, King Faisal University, Al-hofuf, Saudi Arabia

Any reports and responses or comments on the article can be found at the end of the article.

Keywords

SARS-CoV-2, vaccination, clinical trial

This article is included in the **Emerging Diseases and Outbreaks** gateway.

This article is included in the **Coronavirus** collection.

Corresponding author: Etienne Joly (atnjoly@mac.com)

Author roles: Joly E: Conceptualization, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2020 Joly E. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Joly E. **Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications** [version 1; peer review: 3 approved, 1 not approved] F1000Research 2020, 9:309 <https://doi.org/10.12688/f1000research.23480.1>

First published: 29 Apr 2020, 9:309 <https://doi.org/10.12688/f1000research.23480.1>

Identifying the real enemy

As of 21 April, over 2 million cases of Covid-19 have been recorded worldwide and thousands are dying every day (<https://ourworldindata.org/coronavirus>). It is now clear, however, that the virus only kills a small proportion of those it infects, whilst others recover and become immune in a matter of days. The final outcome of this sanitary war is therefore a foregone conclusion, and the survival of the human race is clearly not at stake.

From the above paragraph, it is clear that the true enemy is not the virus, but time. The true question therefore is: how long will it take to resolve the crisis, and at what human and economic costs?

We thus desperately need to identify rapidly a strategy to reach the only situation that will allow us to put an end to confinement: herd immunity. The approach proposed here consists of exploring if the SARS-CoV-2 virus can be turned into an ally to save time towards reaching suitable levels of herd immunity, and with this the resolution of this unprecedented worldwide crisis.

SARS-CoV-2 is a highly contagious virus that has two major peculiarities ([Guan *et al.*, 2020](#); [Zhu *et al.*, 2020](#)):

- The vast majority of serious cases are due to pulmonary complications, following the entry of the virus via the airways and its initial replication in the lungs.
- The morbidity of Covid-19 is massively skewed towards elderly patients, as well as those with pre-existing medical conditions.

It is now clear that the virus causes only mild symptoms in a very significant proportion of the people it infects, and many can even remain completely asymptomatic ([Bendavid *et al.*, 2020](#)). Whilst this is fortunate for those asymptomatic carriers, this is also a major factor that must have contributed to the spread of the virus to every single corner of the inhabited world over the course of just a few weeks.

The only way to evaluate what proportions of various populations have been infected by SARS-CoV-2 will be to carry out surveys of the immunological status of large numbers of people representative of those populations. Serological tests are by far the simplest way to carry out such surveys, but the results of those tests can be relatively tricky to interpret because of significant levels of false positives, due to cross-reactivity with other coronaviruses, and false negatives, due to delayed rise in antibody titres ([Okba *et al.*, 2020](#)), or to a mostly cellular immune response in certain patients ([Jin *et al.*, 2020](#)).

At any rate, the preliminary results of the serological studies carried out on general populations in severely affected areas, where still less than 1% of the population did show clinical signs, seem to suggest that somewhere between 10 and 20% of the population could be already immune to the virus ([Regalado, 2020](#)).

Serological testing will identify people who, having already been infected by SARS-CoV-2 and become immune to it, could come out of confinement and resume a normal life without being a danger to themselves or to others. Several countries are considering issuing sanitary passports to such people. Since there are almost no serious cases in people under 40 years of age with no pre-existing medical condition, if the confinements were to continue for much longer, one could envisage situations in which younger people will start demanding the right to return to a normal life, risking infection by the virus, and thus also risking spreading it to high risk individuals they would interact with. The strategy proposed here represents a possible solution.

Long-lasting confinement will be especially punitive in countries where many people have no source of income unless they go to work. For such people, confinement will rapidly result in starvation, and when hunger hits populations, civil unrest is usually not very far behind. Large numbers of Americans, for example, are employed on “at will” contracts, and have no health benefits. Of greater concern, in several African countries, the confinement imposed by some regimes is predicted to result in the starvation of very large numbers of the poorest people over the coming weeks, due to what has been dubbed ‘Pochvid-20’.

In the strategy proposed here, to speed up the process of developing herd immunity, I suggest taking an approach that would be inconceivable under normal circumstances. Some of the shortcuts suggested here may result in a certain number of casualties. On the other hand, one should not forget that, in the current climate, thousands of people are dying every day, from the virus, in addition to those that are suffering from the consequences of confinement, and that every day saved could thus save as many lives.

Technical aspects

Immunizing with live viruses has long been recognized as the best way to obtain long-lasting immunity, and the skin is well known as a prime site for immunization, yielding responses that are generally skewed towards a type I T helper response ([Zehrung & Kristensen, 2009](#)). A strong, long-lasting cellular immunity raised against the virus itself rather than against a recombinant construct may be the best way to avoid the manifold problems raised by antibody dependent enhancement (ADE) ([Kulkarni, 2020](#); [Ricke & Malone, 2020](#); [Smatti *et al.*, 2018](#)). ADE is one of the major problems that many vaccines developed against lung pathogens have repeatedly encountered over the years. This is one of the reasons why, almost 20 years after the outbreak, we still do not have a vaccine available against SARS-CoV-1, and why a recombinant vaccine against SARS-CoV-2 cannot reasonably be expected to be ready for broad use sooner than 18 months, at the very least ([Ricke & Malone, 2020](#)). On the other hand, the live SARS-CoV-2 virus is the ‘real thing’ and it will have infected well over 2 million people worldwide before the end of this month. Its effects will have been documented better and faster than any other virus before in history, and it is clear by now that lung complications are the primary problem caused by this new virus.

Attenuated viruses have been used to develop very effective vaccines against many of the most lethal viruses, including rabies, yellow fever, polio, measles, mumps, rubella and chicken pox. Some of these vaccines have been found to work after ID inoculation (Hickling *et al.*, 2011; Zehrung & Kristensen, 2009). But obtaining those attenuated viruses took many years of passaging in animals, or in cultured cells, and subsequent testing took at least as long to ensure that the attenuated viruses resulted in suitable immune memory in vaccinated human subjects.

With Covid-19, we do not have this sort of time available, and I would argue that, in the low risk population, the SARS-CoV-2 virus already has the low level of pathogenicity that would make it potentially suitable for a candidate vaccine. Therefore, what I propose to explore is if, by simply changing its route of entry into the organism, one could not turn it into a virus with sufficiently low pathogenicity to be suitable for mass vaccination.

Macaques have already been found to represent a suitable animal model for Covid-19 (Bao *et al.*, 2020; Rockx *et al.*, 2020); recent evidence reports that cats and ferrets (Shi *et al.*, 2020) or hamsters (Chan *et al.*, 2020) could also be used, which would open the way for exploring many more avenues in parallel, provided that suitable facilities for performing experiments on those animals can be identified. On the subject of the inoculation route influencing the distribution of the virus, one should highlight that, in a preliminary study, Deng *et al.* found that one of the two macaques inoculated via the eye's conjunctival route harboured different tissue distributions of viral loads compared to the one macaque inoculated intratracheally (Deng *et al.*, 2020). On this subject, it would be of interest to explore to what extent the different possible routes of contagion by SARS-CoV-2 may contribute to the astounding variability in the intensity of Covid-19 between different patients of similar profiles. Could it be, for example, that lung contagion through aerosols tends to result in more serious clinical outcomes than if the virus is swallowed after passing from hand to mouth?

To bypass the airways, I will argue below that the ID route should be explored as a priority, in one or several of the animal models available if resources permitted it. If the ID route does not result in the efficient triggering of systemic infections, leading to strong immunity and rapid recovery, one could also envisage using subcutaneous, intra-muscular or intra-peritoneal injections, as well as digestive routes, either by ingestion of enterically coated formulations, or via simple intra-rectal (IR) inoculation. If resources permitted, a preferable course of action to save time would be to explore as many of these routes in parallel as possible.

The ID route would, however, seem preferable to the other routes of inoculation, for the following reasons:

- The ID route could also double-up as a skin test, akin to the Mantoux test used to test for BCG-primed immunity. Thus, individuals previously infected by SARS-CoV-2 could be detected in a matter of days. These individuals could then be issued with a

'sero-converted' sanitary passport and resume a normal life (and contribute to running the health care systems and to restarting the countries' economies, without needing to use the protection equipment which is in short supply in so many places).

- It could also boost the immunity of those who have only had mild forms of Covid-19. These people would possibly be at high risk of ADE-related complications in the form of a cytokine storm if they were to be accidentally re-infected by SARS-CoV-2 via the airway route in the course of later months or years, when their level of circulating antibodies would have decreased to sub-neutralizing levels (Ricke & Malone, 2020; Smatti *et al.*, 2018).
- A further advantage of the ID route is that vaccination could be carried out with innocuous material such as micro-needles arrayed on stamps rather than syringes and needles (Kim *et al.*, 2020). And since the virus would only be inoculated into the superficial strata of the skin, the necessary sanitary standards may be more easily attained than for materials destined to be injected with regular needles. Efforts of mass vaccination would therefore be easier to implement.
- To conclude, an advantage of the ID route in my eyes is that with the use of the stamp-like devices carrying micro-needles, volunteers in the early phase trials could self-inoculate the virus, which could circumvent some of the serious ethical issues raised by the approach proposed here.

IR inoculation may turn out to be an alternative to the ID. Indeed, for the IR route, the sanitary considerations would be minimal, and simple dilutions of viral preparations derived directly from tissue culture could conceivably be used. As experience with HIV has shown, some viruses can spread very effectively via the rectal route. Given the fact that ACE-2, the viral receptor, is expressed at very high levels in the digestive tract (see <https://www.proteinatlas.org/ENSG00000130234-ACE2/tissue>), the virus is expected to replicate efficiently in the gut, and consequently to promote strong mucosal immunity. This is supported by the observation that digestive signs are indeed frequent in Covid-19 patients (Pan *et al.*, 2020), but they do not seem to lead to life threatening complications as frequently as in the lungs (<https://www.sciencemag.org/news/2020/04/how-does-coronavirus-kill-clinicians-trace-ferocious-rampage-through-body-brain-toes#>). As an elaboration, one could also conceive of using the IR route as an initial primer, followed by ID inoculation 7 to 10 days later, which would not only boost the immunity, but also provide a direct and sensitive test of the immune status of the recipients.

If the ID or IR routes of inoculation of live SARS-CoV-2 virus were found to cause complications too frequently in the initial stages of the experimentation, a way to work around this undesirable situation may be to use an approach inspired from that used for Polio vaccination nowadays, i.e. the combination of

a recombinant live or inactivated vaccine as a first step, followed by inoculation with live virus. Indeed, two different vaccines were initially developed and used against Polio: the inactivated Salk vaccine, which has limited efficacy, but does not have any serious side effects, and the Sabin vaccine, which is using a live attenuated vaccine (the one that is given to kids on a lump of sugar), and provides lifelong immunity. The major drawback of this live vaccine is that it has been found that the attenuated polio virus rapidly reverts to a wild-type, fully pathogenic virus in the intestine of the vaccinated subjects, who will then expel it in very large numbers in their faeces. This is only a very infrequent problem for the vaccinated subjects themselves (in 1/750,000 cases) (John & Vashishtha, 2013), but is of much more concern for the surrounding family members if they are not vaccinated. Nowadays, the recommended course of action for polio vaccination comprises first an immunisation with the inactivated virus, followed a few weeks later by immunisation with the live attenuated virus.

The logistics of such a two-step approach for fighting Covid-19 would, however, be more complicated than the simple inoculation of live virus in a single step. It has been found that the SARS-CoV-2 can easily be grown to very high titres (10^7 /ml) in cell lines such as Vero, Caco II, or Calu 3 cells (Hoffmann *et al.*, 2020). With just a few tens of litres of infected cultured cells, one would thus expect to have generated enough live virus to inoculate the whole of the world's population. But the amount of viral material could become a limiting factor if a pre-immunisation step had to be carried out. Indeed, even if, accounting for the experience acquired with other intra-dermally applied vaccines, another advantage of the ID route is that it would require less material for the inoculation than other routes, such as subcutaneous or intramuscular (Hickling *et al.*, 2011), immunisation with inactivated virus would require several orders of magnitude more material, and thus much more time to produce, than if just live virus was used. And one of the major disadvantages of using inactivated or recombinant vaccines is that, after the vaccination of the first cohort of volunteers, one has to wait to see if the vaccine is indeed protective, which can take a very long time if one waits for the infections to occur naturally. Others have argued that, in order to save time, one should consider inoculating those volunteers with the virus after vaccination (Eyal *et al.*, 2020); this may, however, raise even more ethical issues than the approach proposed herein, especially if one considers the frequent problems of ADE encountered with vaccines against viruses that can cause lung pathologies (Ricke & Malone, 2020). Personally, given the choice between receiving a live virus via the aerial route after vaccination with a new vaccine or via a route which has been found to seldom lead to lung pathology, I would not hesitate to choose the latter.

The SARS-CoV-2 virus is relatively innocuous for a very large proportion of the population. But a major concern regarding the evolution of this pandemic is that the virus could mutate to become more pathogenic. A further advantage of an approach based on inoculating the virus is that this would

completely block any uncontrolled evolution of the virus, as may happen if it is left to spread through populations by simply lifting confinement. It would also mean that serum obtained from any of the immunised recipients could be used to treat those volunteers that would show complications, without any concern for the fact that the virus may be of a sufficiently divergent source that the transferred antibodies would not neutralise the virus efficiently (Jawhara, 2020).

The anticipated long-run scenario(s)

The hope is that initial experiments carried out on one or several of the available animal models would find that inoculations with live virus via the ID, IR, or some other route will result in the efficient triggering of systemic infections with SARS-CoV-2 with less pulmonary distribution of the virus than the airway inoculation, and hopefully in faster resolution. If this is indeed found to be the case, one could then envisage to setup a first cohort of a few dozens of human volunteers for inoculation with live virus, via the route(s) that will have been identified as the most promising through animal experimentation. Those volunteers would be selected from populations with very low risks of complications. The trial would also have to take place in a completely confined environment, and under close medical monitoring. I suggest that a military base would be a particularly appropriate environment for this type of project.

Furthermore, it does not seem unreasonable to hope that, by then, some therapeutic approaches will have been identified to combat the virus in patients presenting complications. In this regard, passive immunisation with serum from recovered patients seems to be one of the more hopeful avenues to date (Jawhara, 2020; Xie *et al.*, 2020). In the event that one or more volunteers would show signs of serious complications, it is therefore to be hoped that well-defined therapeutic approaches would be at hand by then to prevent truly serious complications from developing in those volunteers.

In an ideal scenario, the course could be as follows:

- 1) Over the coming month, completion of the ID inoculation experiments in macaques (with hamsters, ferrets and/or cats as potential additions).
- 2) During this time, preparations will be made for the first trial on a cohort of a few dozens of volunteers in a completely confined environment. This could take place during the coming month(s), but will obviously only go ahead if and when the results of the above experiments will have shown very promising results.
- 3) If and when the project gets to that stage of self-inoculating by human volunteers, one of the very important aspects of this experimental stage will be to determine how contagious these inoculated volunteers will become, especially whether they excrete a lot of live infectious virus through their airways, urine, or faeces.
- 4) If it is found that, after inoculation, the volunteers are not worryingly contagious, one could conceive of an

exercise of mass immunisation, strictly on volunteers, asking the inoculated volunteers to stay confined at home during the time they generate immunity to SARS-CoV-2.

- 5) On the other hand, if it turned out that inoculated individuals can become highly contagious, one may have to resort to performing the immunisations in confined centres, which I refer to as 'covidodromes'. For this, I envisage that military bases could provide convenient environments, at least for the first stages of the exercise.
- 6) If it turned out that the approach proposed here was truly efficient, and could result in the rapid sero-conversion of thousands of people with a bare minimum of complications, and even fewer casualties, one could then endeavour to step-up the process to be in a position to offer covidodromes for millions of volunteers to travel to and be inoculated with controlled stocks of virus, in a controlled environment. This could for example be achieved by using tourist places which are currently

deserted, such as holiday centres and villages, ski resorts, or even some of the large islands such as those found along the French littoral.

With such a large-scale approach, significant proportions of sero-converted people in the population could be achieved before this summer, ultimately reaching herd immunity, which is the only thing that will allow us to come out of confinement serenely.

Data availability

No data are associated with this article.

Acknowledgements

I am employed by INSERM. I am grateful to Tom McKee for suggesting that the digestive route should be explored in parallel to others, and to Denis Hudrisier for his feedback on an earlier stage of the manuscript.

References

- Bao L, Deng W, Gao H, *et al.*: **Reinfection could not occur in SARS-CoV-2 infected rhesus macaques.** *bioRxiv.* 2020.
[Publisher Full Text](#)
- Bendavid E, Mulaney B, Sood N, *et al.*: **COVID-19 Antibody Seroprevalence in Santa Clara County, California.** *medRxiv.* 2020.
[Publisher Full Text](#)
- Chan JF, Zhang AJ, Yuan S, *et al.*: **Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility.** *Clin Infect Dis.* 2020; pii: ciaa325
[PubMed Abstract](#) | [Publisher Full Text](#)
- Deng W, Bao L, Gao H, *et al.*: **Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route.** *bioRxiv.* 2020.
[Publisher Full Text](#)
- Eyal N, Lipsitch M, Smith PG: **Human challenge studies to accelerate coronavirus vaccine licensure.** *J Infect Dis.* 2020. pii: jiaa152.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Guan WJ, Ni ZY, Hu Y, *et al.*: **Clinical characteristics of coronavirus disease 2019 in China.** *N Engl J Med.* 2020.
[Publisher Full Text](#)
- Hickling JK, Jones KR, Friede M, *et al.*: **Intradermal delivery of vaccines: potential benefits and current challenges.** *Bull World Health Organ.* 2011; 89(3): 221–226.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Hoffmann M, Kleine-Weber H, Schroeder S, *et al.*: **SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.** *Cell.* 2020; 181(2): 271–280.e8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jawhara S: **Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?** *Int J Mol Sci.* 2020; 21(7): pii: E2272
[PubMed Abstract](#) | [Publisher Full Text](#)
- Jin Y, Wang M, Zuo Z, *et al.*: **Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019.** *Int J Infect Dis.* 2020; 94: 49–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
- John TJ, Vashishtha VM: **Eradicating poliomyelitis: India's journey from hyperendemic to polio-free status.** *Indian J Med Res.* 2013; 137(5): 881–894.
[PubMed Abstract](#) | [Free Full Text](#)
- Kim E, Erdos G, Huang S, *et al.*: **Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.** *EBioMedicine.* 2020; 102743.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Kulkarni R: **Antibody-Dependent Enhancement of Viral Infections.** In: Bramhachari, P. V. ed. *Dynamics of immune activation in viral diseases.* Singapore: Springer Singapore, 2020; 9–41.
[Publisher Full Text](#) | [Free Full Text](#)
- Okba NMA, Müller MA, Li W, *et al.*: **Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.** *Emerg Infect Dis.* 2020; 26(7).
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pan L, Mu M, Yang P, *et al.*: **Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study.** *Am J Gastroenterol.* 2020.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Regalado A: **Blood tests show 14% of people are now immune to covid-19 in one town in Germany.** 2020.
[Reference Source](#)
- Ricke DO, Malone RW: **Medical Countermeasures Analysis of 2019-nCoV and Vaccine Risks for Antibody-Dependent Enhancement (ADE).** 2020.
[Publisher Full Text](#)
- Rockx B, Kuiken T, Herfst S, *et al.*: **Comparative Pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model.** *bioRxiv.* 2020.
[Publisher Full Text](#)
- Shi J, Wen Z, Zhong G, *et al.*: **Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2.** *Science.* 2020; Apr 8. pii: eabb7015.
[Publisher Full Text](#)
- Smatti MK, Al Thani AA, Yassine HM: **Viral-Induced Enhanced Disease Illness.** *Front Microbiol.* 2018; 9: 2991.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Xie Y, Cao S, Li Q, *et al.*: **Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19.** *J Infect.* 2020.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zehrung D, Kristensen D: **Intradermal Delivery of Vaccines: A review of the literature and the potential for development for use in low- and middle- income countries.** WHO. 2009.
[Reference Source](#)
- Zhu N, Zhang D, Wang W, *et al.*: **A Novel Coronavirus from Patients with Pneumonia in China, 2019.** *N Engl J Med.* 2020; 382(8): 727–733.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 24 May 2021

<https://doi.org/10.5256/f1000research.25911.r76622>

© 2021 Kandeel M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mahmoud Kandeel

Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al-hofuf, Saudi Arabia

The concept of using live viruses by injection in atypical location might be attractive to some extent and some other researchers had already published on it. However, I am still not encouraged to support this premise as long as safer and effective techniques can be developed. Recently, several vaccines have been approved and widely practiced worldwide, the opinion must be updated.

The application of live viruses for injection of human being can be a matter of virus activation, mutation and infected or immunized persons might be seeding the virus in the surrounding community and act as a source of infection. This application requires also much care, sophisticated resources and extreme care from the medical staff to avoid contact with the live virus.

Despite there are some agreements in the literature, there is no solid evidence for the success of this concept. This manuscript also needs to be updated with the recent findings and approvals in the field of COVID-19 vaccines.

Since the strength of immunity might depend on the amount of virus proteins and poster doses. I am not sure that small amount of live SARS-CoV-2 virus are sufficient to give solid immunity.

Is the topic of the opinion article discussed accurately in the context of the current literature?

No

Are all factual statements correct and adequately supported by citations?

No

Are arguments sufficiently supported by evidence from the published literature?

No

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pharmacology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Reviewer Report 10 May 2021

<https://doi.org/10.5256/f1000research.25911.r66390>

© 2021 Yewdell J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jonathan Yewdell

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA

Joly proposes immunization with live SARS-CoV-2 (CoV2) via non-respiratory routes as a rapidly employable and cost-effective vaccine. This is a brilliant proposal but compromised somewhat by the introduction of highly effective vaccines for COVID-19. I would recommend that the author update the article accordingly and possibly alter the message to incorporate:

1. CoV2 vaccine effectiveness.
2. Advantages of GI immunization for possibly optimizing mucosal immunity. Possibly mention existing enteric adenovirus vaccines used for US military personnel as a relevant example.
3. Make the obvious point that the proposed approach could be rapidly deployed for emerging CoV2 variants or future pandemic with zoonotic virus.

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Adaptive immunity to viruses

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 05 May 2021

<https://doi.org/10.5256/f1000research.25911.r83933>

© 2021 Narayan R et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ravi Kant Narayan

Etiologically Elusive Disorders Research Network (EEDRN), New Delhi, Delhi, India

Manika Verma

Etiologically Elusive Disorders Research Network (EEDRN), New Dehli, Dehli, India

The article proposed the use of unattenuated wild-type SARS-CoV-2 as a live vaccine to be inoculated through routes that can bypass the lungs. Taking into purview the recent trends of the COVID-19 pandemic, the opinion seems to be justified. If we look at the present scenario of the pandemic in India, it would be true to say that the world is going to witness nature's wrath due to human complacency. To avoid further deterioration outside-the-box thinking is required, this article presents the very same.

Recent reports have presented facts that differ from those stated in this article. It mentions "Since there are almost no serious cases in people under 40 years of age with no pre-existing medical condition", this can be now refuted by Abbasi (2020)¹, which mentions the changing scenario of the pandemic with relation to age distribution.

To conclude, I would suggest that the opinion being presented should be experimented with in order to search all the avenues.

References

1. Abbasi J: Younger Adults Caught in COVID-19 Crosshairs as Demographics Shift. *JAMA*. 2020; **324** (21). [Publisher Full Text](#)

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Partly

Are arguments sufficiently supported by evidence from the published literature?

Partly

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Anatomy, Genetics

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 29 July 2020

<https://doi.org/10.5256/f1000research.25911.r68210>

© 2020 Chen J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ji-Ming Chen

College of Veterinary Medicine, Qingdao Agricultural University, Qingdao, China

This article proposed to use a wild-type SARS-CoV-2 as a live vaccine through intradermal, subcutaneous, intra-muscular, or intraperitoneal inoculation, to bypass the pathogenesis site of the fragile lungs. I published three articles discussing the same opinion (PMID: 32320083¹; PMID: 32525587²; PMID: 32681650³). This opinion is supported by the fact that two wild-type adenoviruses have been SAFELY used as live vaccines through enterically coated capsules for 40 years in the US recruits, and reduced over 99% cases of adenovirus-associated acute respiratory diseases (PMID: 27475474⁴). My own experiments also suggested that intra-muscular inoculation of a wild-type respiratory virus is safe and able to induce strong immunity (PMID: 32681650³).

With my own experiment, I do believe that it is POSSIBLE and ONLY possible that intradermal, subcutaneous, or intra-muscular inoculation of SARS-CoV-2 is safe and able to induce strong immunity. We should use animal experiments to confirm this route, and such animal experiments are not expensive as compared with the fact that so many people are dying every day and so much economic loss is happening worldwide.

On the other side, some methods available readily could enhance the safety of the live unattenuated vaccine of COVID-19. For instance, if the SARS-CoV-2 is produced using PK-15 cells rather than Vero cells, it shall carry $\alpha 1,3$ -galactose (α Gal), and thus can form immune complexes with anti- α Gal antibodies which are naturally abundant in human bodies. The anti- α Gal antibodies could greatly enhance the safety of the live unattenuated vaccine through blocking the viral entry,

aiding complements to destroy the virus, and aiding immune cells to destroy the virus (PMID: 32681650³). Meanwhile, the anti-αGal antibodies could greatly enhance the efficacy of the live unattenuated vaccine through immune opsonization, as the immune complexes aid the antigen capture, process and presentation of APCs (PMID: 32681650³). Again, this view should be investigated using animal experiments.

If the above animal experiments strongly support the opinions, the live unattenuated vaccine of COVID-19 should enter clinical trials in the volunteers.

From the view of a veterinary scientist and a long-term worker in public health, I do believe that the live unattenuated vaccine could be much more powerful than the dozens of vaccines currently under rapid development for COVID-19, because the unattenuated vaccine could be of high development speed, high production efficiency, ability to be produced in more countries, all of which could be as important as the safety of vaccine for reducing deaths and losses of the pandemic.

In short, I fully support the major opinions of this view: (1) the unattenuated vaccine could be powerful to curb the COVID-19 pandemic; (2) the unattenuated vaccine is imperatively desired to be investigated using animal experiments. Meanwhile, the author should consider the relevant history, publications, and methods to enhance the safety and efficacy of the unattenuated vaccine.

References

1. Ma QX, Shan H, Zhang CM, Zhang HL, et al.: Decontamination of face masks with steam for mask reuse in fighting the pandemic COVID-19: Experimental supports. *J Med Virol.* 2020. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Chen JM, Sun YX, Chen JW: Potential for elimination of SAR-CoV-2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination. *J Med Virol.* 2020. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Chen JM: SARS-CoV-2 replicating in non-primate mammalian cells probably have critical advantages for COVID-19 vaccines due to anti-Gal antibodies: A minireview and proposals. *J Med Virol.* 2020. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Choudhry A, Mathena J, Albano J, Yacovone M, et al.: Safety evaluation of adenovirus type 4 and type 7 vaccine live, oral in military recruits. *Vaccine.* 2016; **34** (38): 4558-4564 [Publisher Full Text](#)

Is the topic of the opinion article discussed accurately in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Partly

Are arguments sufficiently supported by evidence from the published literature?

Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: public health; veterinary medicine; control of infectious diseases; epidemiology; influenza; virology; evolution

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research